Literature DB >> 23159550

APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease.

Andrew B Wolf1, Richard J Caselli, Eric M Reiman, Jon Valla.   

Abstract

APOE is the major known genetic risk factor for late-onset Alzheimer's disease. Though relationships between APOE-encoded apolipoprotein E and β-amyloid are increasingly well described, mounting evidence supports wide-ranging effects of APOE on the brain. Specifically, APOE appears to affect brain network activity and closely related neuroenergetic functions that might be involved in vulnerability to neurodegenerative pathophysiology. These effects highlight the salience of further investigation into the diverse influences of APOE. Therefore, this article reviews the interplay between APOE and neuroenergetics and proposes areas for further investigation. This research might lead to the identification of novel therapeutic targets for the treatment and/or prevention of Alzheimer's disease.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159550      PMCID: PMC3545040          DOI: 10.1016/j.neurobiolaging.2012.10.011

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  155 in total

1.  Apolipoprotein E4 domain interaction occurs in living neuronal cells as determined by fluorescence resonance energy transfer.

Authors:  Qin Xu; Walter J Brecht; Karl H Weisgraber; Robert W Mahley; Yadong Huang
Journal:  J Biol Chem       Date:  2004-03-30       Impact factor: 5.157

2.  Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.

Authors:  Michael Gold; Claire Alderton; Marina Zvartau-Hind; Sally Egginton; Ann M Saunders; Michael Irizarry; Suzanne Craft; Gary Landreth; Ulla Linnamägi; Sharon Sawchak
Journal:  Dement Geriatr Cogn Disord       Date:  2010-08-21       Impact factor: 2.959

Review 3.  Why glucose transport in the brain matters for PET.

Authors:  L Felipe Barros; Omar H Porras; Carla X Bittner
Journal:  Trends Neurosci       Date:  2005-03       Impact factor: 13.837

4.  Functional magnetic resonance imaging and magnetoencephalography differences associated with APOEepsilon4 in young healthy adults.

Authors:  Francesca M Filbey; Kelly J Slack; Trey P Sunderland; Robert M Cohen
Journal:  Neuroreport       Date:  2006-10-23       Impact factor: 1.837

Review 5.  Multiple pathways for sorting mitochondrial precursor proteins.

Authors:  Natalia Bolender; Albert Sickmann; Richard Wagner; Chris Meisinger; Nikolaus Pfanner
Journal:  EMBO Rep       Date:  2008-01       Impact factor: 8.807

6.  Effect of carboxyl-terminal truncation on structure and lipid interaction of human apolipoprotein E4.

Authors:  Masafumi Tanaka; Charulatha Vedhachalam; Takaaki Sakamoto; Padmaja Dhanasekaran; Michael C Phillips; Sissel Lund-Katz; Hiroyuki Saito
Journal:  Biochemistry       Date:  2006-04-04       Impact factor: 3.162

Review 7.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease.

Authors:  Robert W Mahley; Karl H Weisgraber; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

8.  Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms.

Authors:  K H Weisgraber; S C Rall; R W Mahley
Journal:  J Biol Chem       Date:  1981-09-10       Impact factor: 5.157

9.  Genome-wide pathway analysis implicates intracellular transmembrane protein transport in Alzheimer disease.

Authors:  Mun-Gwan Hong; Andrey Alexeyenko; Jean-Charles Lambert; Philippe Amouyel; Jonathan A Prince
Journal:  J Hum Genet       Date:  2010-07-29       Impact factor: 3.172

10.  Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease.

Authors:  T Gomez-Isla; H L West; G W Rebeck; S D Harr; J H Growdon; J J Locascio; T T Perls; L A Lipsitz; B T Hyman
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

View more
  32 in total

Review 1.  Single Nucleotide Polymorphism in SMAD7 and CHI3L1 and Colorectal Cancer Risk.

Authors:  Amal Ahmed Abd El-Fattah; Nermin Abdel Hamid Sadik; Olfat Gamil Shaker; Amal Mohamed Kamal
Journal:  Mediators Inflamm       Date:  2018-10-25       Impact factor: 4.711

2.  Highly specific SNP detection using 2D graphene electronics and DNA strand displacement.

Authors:  Michael T Hwang; Preston B Landon; Joon Lee; Duyoung Choi; Alexander H Mo; Gennadi Glinsky; Ratnesh Lal
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-13       Impact factor: 11.205

3.  Higher homocysteine associated with thinner cortical gray matter in 803 participants from the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Sarah K Madsen; Priya Rajagopalan; Shantanu H Joshi; Arthur W Toga; Paul M Thompson
Journal:  Neurobiol Aging       Date:  2014-08-30       Impact factor: 4.673

Review 4.  A tale of two systems: Lessons learned from female mid-life aging with implications for Alzheimer's prevention & treatment.

Authors:  Aarti Mishra; Yiwei Wang; Fei Yin; Francesca Vitali; Kathleen E Rodgers; Maira Soto; Lisa Mosconi; Tian Wang; Roberta D Brinton
Journal:  Ageing Res Rev       Date:  2021-12-17       Impact factor: 10.895

Review 5.  Gene-environment interactions in Alzheimer disease: the emerging role of epigenetics.

Authors:  Lucia Migliore; Fabio Coppedè
Journal:  Nat Rev Neurol       Date:  2022-09-30       Impact factor: 44.711

6.  Human APOE ɛ3 and APOE ɛ4 Alleles Have Differential Effects on Mouse Olfactory Epithelium.

Authors:  Naazneen Khan; Yelena Alimova; Sophie J Clark; Hemendra J Vekaria; Adeline E Walsh; Holden C Williams; Gregory S Hawk; Patrick G Sullivan; Lance A Johnson; Timothy S McClintock
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

Review 7.  Apolipoprotein E as a β-amyloid-independent factor in Alzheimer's disease.

Authors:  Andrew B Wolf; Jon Valla; Guojun Bu; Jungsu Kim; Mary Jo LaDu; Eric M Reiman; Richard J Caselli
Journal:  Alzheimers Res Ther       Date:  2013-09-03       Impact factor: 6.982

Review 8.  Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential.

Authors:  Yashi Mi; Guoyuan Qi; Roberta Diaz Brinton; Fei Yin
Journal:  Antioxid Redox Signal       Date:  2020-04-21       Impact factor: 8.401

9.  Metabolic profiling of Alzheimer's disease brains.

Authors:  Koichi Inoue; Haruhito Tsutsui; Hiroyasu Akatsu; Yoshio Hashizume; Noriyuki Matsukawa; Takayuki Yamamoto; Toshimasa Toyo'oka
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

10.  Reduced phosphorylation of brain insulin receptor substrate and Akt proteins in apolipoprotein-E4 targeted replacement mice.

Authors:  Qi-Rui Ong; Elizabeth S Chan; Mei-Li Lim; Gregory M Cole; Boon-Seng Wong
Journal:  Sci Rep       Date:  2014-01-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.